Profile
Sector:
EnergyIndustry:
Oil & Gas MidstreamCountry:
United StatesIPO:
29 September 2005Website:
http://www.globalp.comNext earnings report:
08 November 2024Last dividends:
08 August 2024Next dividends:
08 November 2024Price
after hours | Mon, 04 Nov 2024 21:01:09 GMTAnalysts recommendations
Institutional Ownership
GLP Latest News
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy rating despite FDA uncertainties. Shares rallied ~5% in after-hours trading after the strong Q3 results and raised outlook (~8 points higher on growth and 2 points of additional adjusted EBITDA margin). HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to direct-to-consumer models.
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales forecast higher, as its efforts to offer more personalized care and more weight-loss drugs continue to draw subscribers.
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) blood sugar results from the recently completed animal study WEIGHT-A24-1 (the "Study"). Blood Sugar Levels (mmol/L) DehydraTECH Groups Day 7 Baseline Day 28 % Change to Day 28 Day 56 % Change to Day 56 Day 84 % Change to Day 84 A: CBD1 27.4 26.2 -4.31% 26.9 -1.90% 27.7 1.09% B: CBD2 28.4 29.2 2.73% 26.6 -6.22% 27.3 -3.76% C: CBD3 26.4 24.9 -5.99% 27.1 2.46% 27.5 3.85% D: CBD4 24.6 27.9 13.16% 26.8 8.94% 27.0 9.75% E: Rybelsus1 26.4 25.5 -3.60% 26.8 1.33% 26.8 1.59% w/SNAC F: Rybelsus2 24.9 26.8 7.70% 26.4 5.96% 27.3 9.58% w/SNAC G: Semaglutide 26.3 25.9 -1.52% 27.8 5.54% 26.9 2.13% No SNAC H: Liraglutide 26.4 25.8 -2.08% 25.2 -4.56% 23.3 -11.54% No SNAC Notes - Groups A through D were different DehydraTECH-CBD compositions - Groups E and F were reformulated Rybelsus DehydraTECH compositions - Groups G and H used pure GLP-1 drugs (semaglutide and liraglutide respectively) in DehydraTECH compositions - Recalculations led to slight changes from earlier reported data Lexaria is strongly encouraged that the DehydraTECH-liraglutide and DehydraTECH-CBD groups A and B outperformed all three of the Rybelsus® and pure semaglutide DehydraTECH composition groups regardless of whether the semaglutide had or had not been processed with the salcaprozate sodium technology known as "SNAC".
Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints and early sales success, Madrigal's Q3 earnings will be crucial in determining Rezdiffra's commercial viability and stock performance. The potential for Rezdiffra to achieve blockbuster status is tempered by its high cost and the emerging threat of GLP-1 agonists in the MASH market.
Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024.
Wisp debuts its first-ever exclusive over-the-counter weight-loss supplement, designed to promote women's metabolic health. Wisp introduces personalized, online consultations with access to four weight care solutions, including GLP-1 medications, to support women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis.
REDWOOD CITY, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Wednesday, October 30th at 4:30 pm ET to announce our lead clinical candidate, BMF-650 – a next-generation, potent, selective, oral small-molecule GLP-1 receptor agonist (GLP-1 RA) and to share results of preclinical studies investigating the synergistic benefits of combining BMF-219 with a GLP-1 RA-based therapy.
The future of the weight loss market might not revolve around GLP-1 drugs.
WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs, a move that sent its shares soaring nearly 47%.
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has begun, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) Zepbound® (tirzepatide) in an oral dose format. The Study is being conducted in up to 10 healthy volunteers.
What type of business is Global Partners LP?
Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane to wholesalers, retailers, and commercial customers. The company operates through three segments: Wholesale, Gasoline Distribution and Station Operations, and Commercial. The Wholesale segment sells home heating oil, branded and unbranded gasoline and gasoline blendstocks, diesel, kerosene, and residual oil to home heating oil and propane retailers and wholesale distributors. This segment also transports the products by railcars, barges, trucks and/or pipelines. Its Gasoline Distribution and Station Operations segment sells branded and unbranded gasoline to gasoline station operators and sub-jobbers; operates gasoline stations and convenience stores; and provides car wash, lottery, and ATM services, as well as leases gasoline stations. The Commercial segment sells and delivers unbranded gasoline, home heating oil, diesel, kerosene, residual oil, and bunker fuel to customers in the public sector, as well as to commercial and industrial end-users; and sells custom blended fuels. The company is also involved in the transportation of petroleum products and renewable fuels through rail from the mid-continent region of the United States and Canada. Global Partners LP was founded in 2005 and is based in Waltham, Massachusetts.
What sector is Global Partners LP in?
Global Partners LP is in the Energy sector
What industry is Global Partners LP in?
Global Partners LP is in the Oil & Gas Midstream industry
What country is Global Partners LP from?
Global Partners LP is headquartered in United States
When did Global Partners LP go public?
Global Partners LP initial public offering (IPO) was on 29 September 2005
What is Global Partners LP website?
https://www.globalp.com
Is Global Partners LP in the S&P 500?
No, Global Partners LP is not included in the S&P 500 index
Is Global Partners LP in the NASDAQ 100?
No, Global Partners LP is not included in the NASDAQ 100 index
Is Global Partners LP in the Dow Jones?
No, Global Partners LP is not included in the Dow Jones index
When was Global Partners LP the previous earnings report?
No data
When does Global Partners LP earnings report?
The next expected earnings date for Global Partners LP is 08 November 2024